Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
Finance Minister Hears Out LDP Group’s Emergency Proposal on Off-Year Re-Pricing
The leaders of a study group on pharmaceutical industry issues under the ruling Liberal Democratic Party (LDP) met with Finance Minister Shunichi Suzuki on December 13 to submit an emergency proposal demanding a rethink of the FY2023 “off-year” drug re-pricing.…
To read the full story
Related Article
- Industry Hews to “No” to Off-Year Plan, but Wants Special Steps If It Is to Happen: LDP Confab
December 2, 2022
- LDP Pharma Study Group Calls for Careful Discussions on Off-Year Plan: Proposal
November 25, 2022
- Pro-Industry Lawmakers, Govt Remain Widely Divided over Off-Year Plan
November 11, 2022
- LDP Pharma Study Group Prods Rethink of Annual Re-Pricing, but Health Minister Sounds Negative
June 3, 2022
- LDP Pharma Study Group to Push Price Maintenance for Patented Meds, Rethink of “Off-Year” Re-Pricing towards Honebuto
May 20, 2022
- LDP Pharma Study Group Kicks Off Honebuto Debate, Wants Off-Year Price Cuts Scrapped
April 14, 2022
REGULATORY
- MHLW Lifts Olanzapine Diabetes Contraindication for Antiemetic Use
August 26, 2026
- PMDA Flags Severe Gastritis, Esophagitis with Checkpoint Inhibitors
August 26, 2026
- Japan Grants Sakigake Tag to NS-035, MSA-01
August 26, 2026
- Japan Approves Takeda’s Orzeyful, Insmed’s Brinsupri and More Drugs
August 25, 2026
- Keytruda SC Heads to Japan Approval, Ipsen’s Ojemda for Conditional Nod
August 25, 2026
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…